Liquid Biopsy-Based Colorectal Cancer Screening via Surface Markers of Circulating Tumor Cells
Abstract
:1. Introduction
2. Circulating Tumor Cells Shed Insights toward Liquid Biopsy-based CRC Screening
3. Existing Blood-based Biomarkers Are Not Effective with Low Accuracy
4. “Gold Standard”: Single CTC-Specific Cell Surface Marker-Positive Enrichment
5. Single Specific CSM-based CTC Enrichment Strategy Had Its Limitations
6. Alternative CSMs and Multiplexing Show Potential in Targeting a Wider CTC Population
7. Circulating Cancer Stem Cells Are a Rare CTC Subtype
8. Importance of Enrichment Technique over Selection of CTC Analysis and Characterization in the CRC Screening Stage
9. Stigma on Circulating Tumor Markers in Blood
10. Challenges in Routine Implementation of CTC-Specific CSM-dependent CRC Detection
11. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
Abbreviations
AJCC | American Joint Committee on Cancer |
CCSCCD | Circulating cancer stem cellsCluster of differentiation |
cfDNA | Cell-free DNA |
CK | Cytokeratin |
CRC | Colorectal cancer |
CSM | Cell surface marker |
CTC | Circulating tumor cell |
DAPI | 4′,6-diamidino-2-phenylindole |
EMT | Epithelial–mesenchymal transition |
EpCAM | Epithelial cell adhesion molecule |
FACS | Fluorescent-activated cell sorting |
FCM | Flow cytometry |
FDA | Food and Drug Administration |
KRAS | Kirsten rat sarcoma viral oncogene |
MACS | Magnetic-activated cell sorting |
mCRC | Metastatic CRC |
pan-CK | Pan-cytokeratin |
RT-qPCR | Reverse-transcriptase quantitative polymerase chain reaction |
SE-iFISH | Subtraction enrichment and immunostaining-fluorescence in situ hybridization |
VIM | vimentin |
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019: Cancer Statistics, 2019. CA Cancer J. Clin. 2019, 69, 7–34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Van der Jeught, K.; Xu, H.-C.; Li, Y.-J.; Lu, X.-B.; Ji, G. Drug resistance and new therapies in colorectal cancer. World J. Gastroenterol. 2018, 24, 3834–3848. [Google Scholar] [CrossRef] [PubMed]
- Arvelo, F. Biology of colorectal cancer. Ecancermedicalscience 2015, 9, 520. [Google Scholar] [CrossRef] [Green Version]
- Engstrand, J.; Nilsson, H.; Strömberg, C.; Jonas, E.; Freedman, J. Colorectal cancer liver metastases—A population-based study on incidence, management and survival. BMC Cancer 2018, 18, 78. [Google Scholar] [CrossRef]
- Chakraborty, S.; Rahman, T. The difficulties in cancer treatment. Ecancermedicalscience 2012, 6, ed16. [Google Scholar] [CrossRef]
- Hazewinkel, Y.; Dekker, E. Colonoscopy: Basic principles and novel techniques. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 554–564. [Google Scholar] [CrossRef]
- Makaju, R.; Amatya, M.; Sharma, S.; Dhakal, R.; Bhandari, S.; Shrestha, S.; Gurung, R.; Malla, B. Clinico-Pathological Correlation of Colorectal Diseases by Colonoscopy and Biopsy. Kathmandu Univ. Med. J. 2017, 58, 173–178. [Google Scholar]
- Carroll, M.R.R.; Seaman, H.E.; Halloran, S.P. Tests and investigations for colorectal cancer screening. Clin. Biochem. 2014, 47, 921–939. [Google Scholar] [CrossRef]
- Pox, C.P.; Altenhofen, L.; Brenner, H.; Theilmeier, A.; Stillfried, D.V.; Schmiegel, W. Efficacy of a Nationwide Screening Colonoscopy Program for Colorectal Cancer. Gastroenterology 2012, 142, 1460–1467.e2. [Google Scholar] [CrossRef]
- Marzouk, O.; Schofield, J. Review of Histopathological and Molecular Prognostic Features in Colorectal Cancer. Cancers 2011, 3, 2767–2810. [Google Scholar] [CrossRef] [Green Version]
- Amin, M.B.; Greene, F.L.; Edge, S.B.; Compton, C.C.; Gershenwald, J.E.; Brookland, R.K.; Meyer, L.; Gress, D.M.; Byrd, D.R.; Winchester, D.P. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J. Clin. 2017, 67, 93–99. [Google Scholar] [CrossRef]
- Kim, A. Imaging Diagnosis of Colorectal Cancer. J. Korean Med. Assoc. 2010, 53, 562–568. [Google Scholar] [CrossRef] [Green Version]
- Brenner, H.; Hoffmeister, M.; Arndt, V.; Stegmaier, C.; Altenhofen, L.; Haug, U. Protection from Right- and Left-Sided Colorectal Neoplasms After Colonoscopy: Population-Based Study. J. Natl Cancer Inst. 2010, 102, 89–95. [Google Scholar] [CrossRef] [Green Version]
- Lansdorp-Vogelaar, I.; Knudsen, A.B.; Brenner, H. Cost-effectiveness of colorectal cancer screening. Epidemiol. Rev. 2011, 33, 88–100. [Google Scholar] [CrossRef] [Green Version]
- Punt, C.J.A.; Koopman, M.; Vermeulen, L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat. Rev. Clin. Oncol. 2017, 14, 235–246. [Google Scholar] [CrossRef]
- Wolf, A.M.D.; Fontham, E.T.H.; Church, T.R.; Flowers, C.R.; Guerra, C.E.; LaMonte, S.J.; Etzioni, R.; McKenna, M.T.; Oeffinger, K.C.; Shih, Y.-C.T.; et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J. Clin. 2018, 68, 250–281. [Google Scholar] [CrossRef]
- Zhai, Z.; Yu, X.; Yang, B.; Zhang, Y.; Zhang, L.; Li, X.; Sun, H. Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance. Semin. Cell Dev. Biol. 2017, 64, 107–115. [Google Scholar] [CrossRef]
- Shaukat, A.; Mongin, S.J.; Geisser, M.S.; Lederle, F.A.; Bond, J.H.; Mandel, J.S.; Church, T.R. Long-term mortality after screening for colorectal cancer. N. Engl. J. Med. 2013, 369, 1106–1114. [Google Scholar] [CrossRef]
- Batth, I.S.; Mitra, A.; Manier, S.; Ghobrial, I.M.; Menter, D.; Kopetz, S.; Li, S. Circulating tumor markers: Harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Ann. Oncol. 2017, 28, 468–477. [Google Scholar] [CrossRef]
- Marcuello, M.; Vymetalkova, V.; Neves, R.P.L.; Duran-Sanchon, S.; Vedeld, H.M.; Tham, E.; van Dalum, G.; Flügen, G.; Garcia-Barberan, V.; Fijneman, R.J.; et al. Circulating biomarkers for early detection and clinical management of colorectal cancer. Mol. Asp. Med. 2019, 69, 107–122. [Google Scholar] [CrossRef]
- Micalizzi, D.S.; Maheswaran, S.; Haber, D.A. A conduit to metastasis: Circulating tumor cell biology. Genes Dev. 2017, 31, 1827–1840. [Google Scholar] [CrossRef]
- Dive, C.; Brady, G. SnapShot: Circulating Tumor Cells. Cell 2017, 168, 742–742.e1. [Google Scholar] [CrossRef]
- Hardingham, J.E.; Grover, P.; Winter, M.; Hewett, P.J.; Price, T.J.; Thierry, B. Detection and Clinical Significance of Circulating Tumor Cells in Colorectal Cancer—20 Years of Progress. Mol. Med. 2015, 21, S25–S31. [Google Scholar] [CrossRef]
- Hardingham, J.E.; Hewett, P.J.; Sage, R.E.; Finch, J.L.; Nuttall, J.D.; Kotasek, D.; Dobrovic, A. Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int. J. Cancer 2000, 89, 8–13. [Google Scholar] [CrossRef]
- Pantel, K.; Speicher, M.R. The biology of circulating tumor cells. Oncogene 2016, 35, 1216–1224. [Google Scholar] [CrossRef]
- Pantel, K.; Denève, E.; Nocca, D.; Coffy, A.; Vendrell, J.-P.; Maudelonde, T.; Riethdorf, S.; Alix-Panabières, C. Circulating epithelial cells in patients with benign colon diseases. Clin. Chem. 2012, 58, 936–940. [Google Scholar] [CrossRef]
- Souza, E.; Silva, V.; Abdallah, E.A.; de Mello, C.A.L.; Tariki, M.S.; Calsavara, V.F.; Chinen, L.T.D. Prospective study with circulating tumor cells as potential prognosis biomarker in metastatic colorectal cancer. JCO 2020, 38, 203. [Google Scholar] [CrossRef]
- Freeman, J.; Gray, E.S.; Ziman, M. Circulating Tumor Cells as Biomarkers in Cancer. In Biomarkers in Cancer. Biomarkers in Disease: Methods, Discoveries and Applications; Preedy, V., Patel, V., Eds.; Springer: Dordrecht, The Netherlands, 2015; pp. 31–51. [Google Scholar] [CrossRef]
- Tsai, W.-S.; You, J.-F.; Hung, H.-Y.; Hsieh, P.-S.; Hsieh, B.; Lenz, H.-J.; Idos, G.; Friedland, S.; Yi-Jiun Pan, J.; Shao, H.-J.; et al. Novel Circulating Tumor Cell Assay for Detection of Colorectal Adenomas and Cancer. Clin. Transl. Gastroenterol. 2019, 10, e00088. [Google Scholar] [CrossRef]
- Chang, Y.S.; di Tomaso, E.; McDonald, D.M.; Jones, R.; Jain, R.K.; Munn, L.L. Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood. Proc. Natl. Acad. Sci. USA 2000, 97, 14608–14613. [Google Scholar] [CrossRef] [Green Version]
- Tamimi, Y. Micrometastatic Circulating Tumor cells; A Challenge for an Early Detection and Better Survival Rates. J. Carcinog. Mutagenesis 2015, 6, 9. [Google Scholar]
- Oakman, C.; Pestrin, M.; Bessi, S.; Galardi, F.; Di Leo, A. Significance of Micrometastases: Circulating Tumor Cells and Disseminated Tumor Cells in Early Breast Cancer. Cancers 2010, 2, 1221–1235. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Koyanagi, K.; Bilchik, A.J.; Saha, S.; Turner, R.R.; Wiese, D.; McCarter, M.; Shen, P.; Deacon, L.; Elashoff, D.; Hoon, D.S.B. Prognostic Relevance of Occult Nodal Micrometastases and Circulating Tumor Cells in Colorectal Cancer in a Prospective Multicenter Trial. Clin. Cancer Res. 2008, 14, 7391–7396. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Molnar, B.; Floro, L.; Sipos, F.; Toth, B.; Sreter, L.; Tulassay, Z. Elevation in Peripheral Blood Circulating Tumor Cell Number Correlates with Macroscopic Progression in UICC Stage IV Colorectal Cancer Patients. Available online: https://www.hindawi.com/journals/dm/2008/941509/ (accessed on 1 October 2020).
- De Wit, S.; van Dalum, G.; Terstappen, L.W.M.M. Detection of Circulating Tumor Cells. Available online: https://www.hindawi.com/journals/scientifica/2014/819362/ (accessed on 1 October 2020).
- Ferreira, M.M.; Ramani, V.C.; Jeffrey, S.S. Circulating tumor cell technologies. Mol. Oncol. 2016, 10, 374–394. [Google Scholar] [CrossRef] [Green Version]
- Thery, L.; Meddis, A.; Cabel, L.; Proudhon, C.; Latouche, A.; Pierga, J.-Y.; Bidard, F.-C. Circulating Tumor Cells in Early Breast Cancer. JNCI Cancer Spectr. 2019, 3, pkz026. [Google Scholar] [CrossRef]
- Allard, W.J.; Terstappen, L.W.M.M. CCR 20th Anniversary Commentary: Paving the Way for Circulating Tumor Cells. Clin. Cancer Res. 2015, 21, 2883–2885. [Google Scholar] [CrossRef] [Green Version]
- Tieng, F.Y.F.; Baharudin, R.; Abu, N.; Mohd Yunos, R.-I.; Lee, L.-H.; Ab Mutalib, N.-S. Single Cell Transcriptome in Colorectal Cancer—Current Updates on Its Application in Metastasis, Chemoresistance and the Roles of Circulating Tumor Cells. Front. Pharmacol. 2020, 11, 135. [Google Scholar] [CrossRef] [Green Version]
- Tieng, F.Y.F.; Abu, N.; Lee, L.-H.; Ab Mutalib, N.-S. Microsatellite Instability in Colorectal Cancer Liquid Biopsy—Current Updates on Its Potential in Non-Invasive Detection, Prognosis and as a Predictive Marker. Diagnostics 2021, 11, 544. [Google Scholar] [CrossRef]
- Berretta, M.; Alessandrini, L.; De Divitiis, C.; Nasti, G.; Lleshi, A.; Di Francia, R.; Facchini, G.; Cavaliere, C.; Buonerba, C.; Canzonieri, V. Serum and tissue markers in colorectal cancer: State of art. Crit. Rev. Oncol. Hematol. 2017, 111, 103–116. [Google Scholar] [CrossRef]
- Bhardwaj, M.; Gies, A.; Werner, S.; Schrotz-King, P.; Brenner, H. Blood-Based Protein Signatures for Early Detection of Colorectal Cancer: A Systematic Review. Clin. Transl. Gastroenterol. 2017, 8, e128. [Google Scholar] [CrossRef]
- Huang, Z.; Huang, D.; Ni, S.; Peng, Z.; Sheng, W.; Du, X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer 2010, 127, 118–126. [Google Scholar] [CrossRef]
- Liu, Z.; Zhang, Y.; Niu, Y.; Li, K.; Liu, X.; Chen, H.; Gao, C. A Systematic Review and Meta-Analysis of Diagnostic and Prognostic Serum Biomarkers of Colorectal Cancer. PLoS ONE 2014, 9, e103910. [Google Scholar] [CrossRef]
- Tieng, F.Y.F.; Abu, N.; Sukor, S.; Mohd Azman, Z.A.; Mahamad Nadzir, N.; Lee, L.-H.; Ab Mutalib, N.S. L1CAM, CA9, KLK6, HPN, and ALDH1A1 as Potential Serum Markers in Primary and Metastatic Colorectal Cancer Screening. Diagnostics 2020, 10, 444. [Google Scholar] [CrossRef]
- Torres, A.; Pac-Sosińska, M.; Wiktor, K.; Paszkowski, T.; Maciejewski, R.; Torres, K. CD44, TGM2 and EpCAM as novel plasma markers in endometrial cancer diagnosis. BMC Cancer 2019, 19, 401. [Google Scholar] [CrossRef]
- Vatandoost, N.; Ghanbari, J.; Mojaver, M.; Avan, A.; Ghayour-Mobarhan, M.; Nedaeinia, R.; Salehi, R. Early detection of colorectal cancer: From conventional methods to novel biomarkers. J. Cancer Res. Clin. Oncol. 2016, 142, 341–351. [Google Scholar] [CrossRef]
- Hon, K.W.; Abu, N.; Ab Mutalib, N.-S.; Jamal, R. Exosomes as Potential Biomarkers and Targeted Therapy in Colorectal Cancer: A Mini-Review. Front. Pharmacol. 2017, 8, 583. [Google Scholar] [CrossRef] [Green Version]
- Huang, M.-Y.; Tsai, H.-L.; Huang, J.-J.; Wang, J.-Y. Clinical Implications and Future Perspectives of Circulating Tumor Cells and Biomarkers in Clinical Outcomes of Colorectal Cancer. Transl. Oncol. 2016, 9, 340–347. [Google Scholar] [CrossRef] [Green Version]
- Kanaan, Z.; Roberts, H.; Eichenberger, M.; Billeter, A.; Ocheretner, G.; Pan, J.; Rai, S.; Jorden, J.; Williford, A.; Galandiuk, S. A Plasma MicroRNA Panel for Detection of Colorectal Adenomas: A Step Toward More Precise Screening for Colorectal Cancer. Ann. Surg. 2013, 258, 400–408. [Google Scholar] [CrossRef]
- Bünger, S.; Haug, U.; Kelly, F.M.; Klempt-Giessing, K.; Cartwright, A.; Posorski, N.; Dibbelt, L.; Fitzgerald, S.P.; Bruch, H.-P.; Roblick, U.J.; et al. Toward standardized high-throughput serum diagnostics: Multiplex-protein array identifies IL-8 and VEGF as serum markers for colon cancer. J. Biomol. Screen 2011, 16, 1018–1026. [Google Scholar] [CrossRef] [Green Version]
- Vocka, M.; Langer, D.; Fryba, V.; Petrtyl, J.; Hanus, T.; Kalousova, M.; Zima, T.; Petruzelka, L. Novel serum markers HSP60, CHI3L1, and IGFBP-2 in metastatic colorectal cancer. Oncol. Lett. 2019, 18, 6284–6292. [Google Scholar] [CrossRef]
- Imperiale, T.F.; Imperiale, T.F. Noninvasive Screening Tests for Colorectal Cancer. DDI 2012, 30, 16–26. [Google Scholar] [CrossRef]
- Hanke, B.; Riedel, C.; Lampert, S.; Happich, K.; Martus, P.; Parsch, H.; Himmler, B.; Hohenberger, W.; Hahn, E.G.; Wein, A. CEA and CA19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA). Ann. Oncol. 2001, 12, 221–226. [Google Scholar] [CrossRef]
- Hauptman, N.; Glavač, D. Colorectal Cancer Blood-Based Biomarkers. Gastroenterol. Res. Pr. 2017, 2017. [Google Scholar] [CrossRef] [Green Version]
- Negm, R.S.; Verma, M.; Srivastava, S. The promise of biomarkers in cancer screening and detection. Trends Mol. Med. 2002, 8, 288–293. [Google Scholar] [CrossRef]
- Rupert, K.; Holubec, L.; Nosek, J.; Houdek, K.; Topolcan, O.; Treska, V. Significance of the TPS cytokeratin marker in the postoperative follow up of colorectal carcinoma patients. Rozhl. Chir. 2009, 88, 428–433. [Google Scholar] [PubMed]
- Świderska, M.; Choromańska, B.; Dąbrowska, E.; Konarzewska-Duchnowska, E.; Choromańska, K.; Szczurko, G.; Myśliwiec, P.; Dadan, J.; Ładny, J.R.; Zwierz, K. The diagnostics of colorectal cancer. Contemp. Oncol. 2014, 18, 1–6. [Google Scholar] [CrossRef]
- Locker, G.Y.; Hamilton, S.; Harris, J.; Jessup, J.M.; Kemeny, N.; Macdonald, J.S.; Somerfield, M.R.; Hayes, D.F.; Bast, R.C.; ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 2006, 24, 5313–5327. [Google Scholar] [CrossRef] [PubMed]
- Guadagni, F.; Roselli, M.; Cosimelli, M.; Mannella, E.; Tedesco, M.; Cavaliere, F.; Grassi, A.; Abbolito, M.R.; Greiner, J.W.; Schlom, J. TAG-72 (CA 72-4 assay) as a complementary serum tumor antigen to carcinoembryonic antigen in monitoring patients with colorectal cancer. Cancer 1993, 72, 2098–2106. [Google Scholar] [CrossRef]
- Jelski, W.; Mroczko, B. Biochemical Markers of Colorectal Cancer—Present and Future. Cancer Manag. Res. 2020, 12, 4789–4797. [Google Scholar] [CrossRef]
- Quentmeier, A.; Möller, P.; Schwarz, V.; Abel, U.; Schlag, P. Carcinoembryonic antigen, CA 19-9, and CA 125 in normal and carcinomatous human colorectal tissue. Cancer 1987, 60, 2261–2266. [Google Scholar] [CrossRef]
- Ryan, E.J.; Creagh, E.M. Emerging methods in colorectal cancer screening. Br. J. Surg. 2018, 105, e16–e18. [Google Scholar] [CrossRef] [Green Version]
- Tian, C.; Xu, X.; Wang, Y.; Li, D.; Lu, H.; Yang, Z. Development and Clinical Prospects of Techniques to Separate Circulating Tumor Cells from Peripheral Blood. Cancer Manag. Res. 2020, 12, 7263–7275. [Google Scholar] [CrossRef]
- Hayes, D.F.; Smerage, J.B. Circulating Tumor Cells. In Progress in Molecular Biology and Translational Science; Elsevier: Amsterdam, The Netherlands, 2010; Volume 95, pp. 95–112. [Google Scholar] [CrossRef]
- Krebs, M.G.; Hou, J.-M.; Ward, T.H.; Blackhall, F.H.; Dive, C. Circulating tumour cells: Their utility in cancer management and predicting outcomes. Ther. Adv. Med. Oncol. 2010, 2, 351–365. [Google Scholar] [CrossRef] [Green Version]
- Miller, M.C.; Doyle, G.V.; Terstappen, L.W.M.M. Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J. Oncol. 2010, 2010, 617421. [Google Scholar] [CrossRef]
- Andree, K.C.; van Dalum, G.; Terstappen, L.W.M.M. Challenges in circulating tumor cell detection by the CellSearch system. Mol. Oncol. 2016, 10, 395–407. [Google Scholar] [CrossRef] [Green Version]
- Van der Toom, E.E.; Verdone, J.E.; Gorin, M.A.; Pienta, K.J. Technical challenges in the isolation and analysis of circulating tumor cells. Oncotarget 2016, 7, 62754–62766. [Google Scholar] [CrossRef] [Green Version]
- Zou, D.; Cui, D. Advances in isolation and detection of circulating tumor cells based on microfluidics. Cancer Biol. Med. 2018, 15, 335–353. [Google Scholar] [CrossRef] [Green Version]
- Vafaei, S.; Roudi, R.; Madjd, Z.; Aref, A.R.; Ebrahimi, M. Potential theranostics of circulating tumor cells and tumor-derived exosomes application in colorectal cancer. Cancer Cell Int. 2020, 20, 288. [Google Scholar] [CrossRef]
- Bankó, P.; Lee, S.Y.; Nagygyörgy, V.; Zrínyi, M.; Chae, C.H.; Cho, D.H.; Telekes, A. Technologies for circulating tumor cell separation from whole blood. J. Hematol. Oncol. 2019, 12, 48. [Google Scholar] [CrossRef] [Green Version]
- Rothé, F.; Maetens, M.; Rouas, G.; Paesmans, M.; Van den Eynde, M.; Van Laethem, J.-L.; Vergauwe, P.; Deboever, G.; Bareche, Y.; Vandeputte, C.; et al. CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: A companion study to the PePiTA trial. BMC Cancer 2019, 19, 304. [Google Scholar] [CrossRef] [Green Version]
- Cristofanilli, M.; Budd, G.T.; Ellis, M.J.; Stopeck, A.; Matera, J.; Miller, M.C.; Reuben, J.M.; Doyle, G.V.; Allard, W.J.; Terstappen, L.W.M.M.; et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004, 351, 781–791. [Google Scholar] [CrossRef] [Green Version]
- Millner, L.M.; Linder, M.W.; Valdes, R. Circulating Tumor Cells: A Review of Present Methods and the Need to Identify Heterogeneous Phenotypes. Ann. Clin. Lab. Sci. 2013, 43, 295–304. [Google Scholar] [PubMed]
- Cohen, S.J.; Punt, C.J.A.; Iannotti, N.; Saidman, B.H.; Sabbath, K.D.; Gabrail, N.Y.; Picus, J.; Morse, M.A.; Mitchell, E.; Miller, M.C.; et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann. Oncol. 2009, 20, 1223–1229. [Google Scholar] [CrossRef]
- Cohen, S.J.; Punt, C.J.; lannotti, N.; Saidman, B.H.; Sabbath, K.D.; Gabrail, N.Y.; Picus, J.; Morse, M.; Mitchell, E.; Miller, M.C.; et al. Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients with Metastatic Colorectal Cancer. J. Clin. Oncol. 2008, 26, 3213–3221. [Google Scholar] [CrossRef]
- Mamdouhi, T.; Twomey, J.D.; McSweeney, K.M.; Zhang, B. Fugitives on the run: Circulating tumor cells (CTCs) in metastatic diseases. Cancer Metastasis Rev. 2019, 38, 297–305. [Google Scholar] [CrossRef] [Green Version]
- Kowalik, A.; Kowalewska, M.; Góźdź, S. Current approaches for avoiding the limitations of circulating tumor cells detection methods—implications for diagnosis and treatment of patients with solid tumors. Transl. Res. 2017, 185, 58–84.e15. [Google Scholar] [CrossRef] [Green Version]
- Lin, Z.; Luo, G.; Du, W.; Kong, T.; Liu, C.; Liu, Z. Recent Advances in Microfluidic Platforms Applied in Cancer Metastasis: Circulating Tumor Cells’ (CTCs) Isolation and Tumor-On-A-Chip. Small 2020, 16, 1903899. [Google Scholar] [CrossRef]
- Gupta, P.; Gulzar, Z.; Hsieh, B.; Lim, A.; Watson, D.; Mei, R. Analytical validation of the CellMax platform for early detection of cancer by enumeration of rare circulating tumor cells. J. Circ. Biomark. 2019, 8, 1849454419899214. [Google Scholar] [CrossRef]
- Kure, K.; Hosoya, M.; Ueyama, T.; Fukaya, M.; Sugimoto, K.; Tomiki, Y.; Ohnaga, T.; Sakamoto, K.; Komiyama, H. Using the polymeric circulating tumor cell chip to capture circulating tumor cells in blood samples of patients with colorectal cancer. Oncol. Lett 2020, 19, 2286–2294. [Google Scholar] [CrossRef] [Green Version]
- Toh, J.W.T.; Lim, S.H.; MacKenzie, S.; de Souza, P.; Bokey, L.; Chapuis, P.; Spring, K.J. Association between Microsatellite Instability Status and Peri-Operative Release of Circulating Tumour Cells in Colorectal Cancer. Cells 2020, 9, 425. [Google Scholar] [CrossRef] [Green Version]
- Mármol, I.; Sánchez-de-Diego, C.; Pradilla Dieste, A.; Cerrada, E.; Rodriguez Yoldi, M.J. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. Int. J. Mol. Sci. 2017, 18, 197. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huels, D.J.; Sansom, O.J. Stem vs non-stem cell origin of colorectal cancer. Br. J. Cancer 2015, 113, 1–5. [Google Scholar] [CrossRef] [PubMed]
- Eslami-S, Z.; Cortés-Hernández, L.E.; Alix-Panabières, C. Epithelial Cell Adhesion Molecule: An Anchor to Isolate Clinically Relevant Circulating Tumor Cells. Cells 2020, 9, 1836. [Google Scholar] [CrossRef] [PubMed]
- Alix-Panabières, C.; Mader, S.; Pantel, K. Epithelial-mesenchymal plasticity in circulating tumor cells. J. Mol. Med. 2017, 95, 133–142. [Google Scholar] [CrossRef] [PubMed]
- Fischer, K.R.; Durrans, A.; Lee, S.; Sheng, J.; Li, F.; Wong, S.T.C.; Choi, H.; El Rayes, T.; Ryu, S.; Troeger, J.; et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015, 527, 472–476. [Google Scholar] [CrossRef]
- Yu, M.; Bardia, A.; Wittner, B.S.; Stott, S.L.; Smas, M.E.; Ting, D.T.; Isakoff, S.J.; Ciciliano, J.C.; Wells, M.N.; Shah, A.M.; et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013, 339, 580–584. [Google Scholar] [CrossRef] [Green Version]
- Zheng, X.; Carstens, J.L.; Kim, J.; Scheible, M.; Kaye, J.; Sugimoto, H.; Wu, C.-C.; LeBleu, V.S.; Kalluri, R. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015, 527, 525–530. [Google Scholar] [CrossRef] [Green Version]
- Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009, 119, 1420–1428. [Google Scholar] [CrossRef] [Green Version]
- Dongre, A.; Weinberg, R.A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 2019, 20, 69–84. [Google Scholar] [CrossRef]
- Barrière, G.; Tartary, M.; Rigaud, M. Epithelial Mesenchymal Transition: A New Insight into the Detection of Circulating Tumor Cells. Available online: https://www.hindawi.com/journals/isrn/2012/382010/ (accessed on 21 February 2021).
- Zhao, R.; Cai, Z.; Li, S.; Cheng, Y.; Gao, H.; Liu, F.; Wu, S.; Liu, S.; Dong, Y.; Zheng, L.; et al. Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer. Oncotarget 2017, 8, 9293–9302. [Google Scholar] [CrossRef] [Green Version]
- Dizdar, L.; Fluegen, G.; van Dalum, G.; Honisch, E.; Neves, R.P.; Niederacher, D.; Neubauer, H.; Fehm, T.; Rehders, A.; Krieg, A.; et al. Detection of circulating tumor cells in colorectal cancer patients using the GILUPI CellCollector: Results from a prospective, single-center study. Mol. Oncol. 2019, 13, 1548–1558. [Google Scholar] [CrossRef] [Green Version]
- Kang, H.; Kim, J.; Cho, H.; Han, K.-H. Evaluation of Positive and Negative Methods for Isolation of Circulating Tumor Cells by Lateral Magnetophoresis. Micromachines 2019, 10, 386. [Google Scholar] [CrossRef] [Green Version]
- Bahnassy, A.A.; Salem, S.E.; Mohanad, M.; Abulezz, N.Z.; Abdellateif, M.S.; Hussein, M.; Zekri, C.A.N.; Zekri, A.-R.N.; Allahloubi, N.M.A. Prognostic significance of circulating tumor cells (CTCs) in Egyptian non-metastatic colorectal cancer patients: A comparative study for four different techniques of detection (Flowcytometry, CellSearch, Quantitative Real-time PCR and Cytomorphology). Exp. Mol. Pathol. 2019, 106, 90–101. [Google Scholar] [CrossRef]
- Wang, L.; Zhou, S.; Zhang, W.; Wang, J.; Wang, M.; Hu, X.; Liu, F.; Zhang, Y.; Jiang, B.; Yuan, H. Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: A retrospective study in 121 patients. Int. J. Colorectal Dis. 2019, 34, 589–597. [Google Scholar] [CrossRef] [Green Version]
- Soler, A.; Cayrefourcq, L.; Mazel, M.; Alix-Panabières, C. EpCAM-Independent Enrichment and Detection of Viable Circulating Tumor Cells Using the EPISPOT Assay. In Circulating Tumor Cells: Methods and Protocols; Magbanua, M.J.M., Park, J.W., Eds.; Methods in Molecular Biology; Springer: New York, NY, USA, 2017; Volume 1634, pp. 263–276. [Google Scholar] [CrossRef]
- Huang, T.; Xu, C.; Xiao, J.; Wang, Q.; Wang, Y.; Zhang, Y.; Bai, D.; Zhou, F.; Zhao, X. Determination of the optimal detection time of circulating tumor cells for the postoperative monitoring of colorectal cancer. Oncol. Lett. 2020, 19, 2996–3002. [Google Scholar] [CrossRef]
- Hamid, F.-B.; Islam, F.; Lu, C.-T.; Matos, M.; Cheng, T.; Gopalan, V.; Lam, A.K. Abstract 5367: Identification and clinical value of the circulating tumor cells (CTCs) in the colorectal cancer. Cancer Res. 2020, 80, 5367. [Google Scholar] [CrossRef]
- Bahrami, A.; Hassanian, S.M.; ShahidSales, S.; Farjami, Z.; Hasanzadeh, M.; Anvari, K.; Aledavood, A.; Maftouh, M.; Ferns, G.A.; Khazaei, M.; et al. Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer. J. Cell. Physiol. 2018, 233, 2058–2066. [Google Scholar] [CrossRef]
- Neuzillet, C.; Tijeras-Raballand, A.; de Mestier, L.; Cros, J.; Faivre, S.; Raymond, E. MEK in cancer and cancer therapy. Pharmacol. Ther. 2014, 141, 160–171. [Google Scholar] [CrossRef]
- Prieur, A.; Cappellini, M.; Habif, G.; Lefranc, M.-P.; Mazard, T.; Morency, E.; Pascussi, J.-M.; Flacelière, M.; Cahuzac, N.; Vire, B.; et al. Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer. Clin. Cancer Res. 2017, 23, 5267–5280. [Google Scholar] [CrossRef] [Green Version]
- Sullivan, K.M.; Kozuch, P.S. Impact of KRAS Mutations on Management of Colorectal Carcinoma. Available online: https://www.hindawi.com/journals/pri/2011/219309/ (accessed on 21 February 2021).
- Amado, R.G.; Wolf, M.; Peeters, M.; Van Cutsem, E.; Siena, S.; Freeman, D.J.; Juan, T.; Sikorski, R.; Suggs, S.; Radinsky, R.; et al. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients with Metastatic Colorectal Cancer. JCO 2008, 26, 1626–1634. [Google Scholar] [CrossRef]
- Allegra, C.J.; Jessup, J.M.; Somerfield, M.R.; Hamilton, S.R.; Hammond, E.H.; Hayes, D.F.; McAllister, P.K.; Morton, R.F.; Schilsky, R.L. American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients with Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy. JCO 2009, 27, 2091–2096. [Google Scholar] [CrossRef] [Green Version]
- De Roock, W.; Claes, B.; Bernasconi, D.; De Schutter, J.; Biesmans, B.; Fountzilas, G.; Kalogeras, K.T.; Kotoula, V.; Papamichael, D.; Laurent-Puig, P.; et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol. 2010, 11, 753–762. [Google Scholar] [CrossRef]
- Van Cutsem, E.; Lenz, H.-J.; Köhne, C.-H.; Heinemann, V.; Tejpar, S.; Melezínek, I.; Beier, F.; Stroh, C.; Rougier, P.; van Krieken, J.H.; et al. Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer. JCO 2015, 33, 692–700. [Google Scholar] [CrossRef] [Green Version]
- Feng, C.; Wang, J.; Yang, X.; Zang, X.; Zhou, H.; Zhang, E.; Li, H.; Liu, B.; Chen, S.; Wang, Y.; et al. Construction and Characterization of KRAS Immune Lipid Magnetic Balls for Colorectal Cancer Circulating Tumor Cells. Cancer Manag. Res. 2020, 12, 10067–10075. [Google Scholar] [CrossRef]
- Lopresti, A.; Malergue, F.; Bertucci, F.; Liberatoscioli, M.L.; Garnier, S.; DaCosta, Q.; Finetti, P.; Gilabert, M.; Raoul, J.L.; Birnbaum, D.; et al. Sensitive and easy screening for circulating tumor cells by flow cytometry. JCI Insight 2019, 4, e128180. [Google Scholar] [CrossRef] [Green Version]
- Wilson, R.E.; O’Connor, R.; Gallops, C.E.; Kwizera, E.A.; Noroozi, B.; Morshed, B.I.; Wang, Y.; Huang, X. Immunomagnetic Capture and Multiplexed Surface Marker Detection of Circulating Tumor Cells with Magnetic Multicolor Surface-Enhanced Raman Scattering Nanotags. ACS Appl. Mater. Interfaces 2020, 12, 47220–47232. [Google Scholar] [CrossRef]
- Agnoletto, C.; Corrà, F.; Minotti, L.; Baldassari, F.; Crudele, F.; Cook, W.J.J.; Di Leva, G.; d’Adamo, A.P.; Gasparini, P.; Volinia, S. Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset. Cancers 2019, 11, 483. [Google Scholar] [CrossRef] [Green Version]
- Grillet, F.; Bayet, E.; Villeronce, O.; Zappia, L.; Lagerqvist, E.L.; Lunke, S.; Charafe-Jauffret, E.; Pham, K.; Molck, C.; Rolland, N.; et al. Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture. Gut 2017, 66, 1802–1810. [Google Scholar] [CrossRef] [Green Version]
- Barbazán, J.; Alonso-Alconada, L.; Muinelo-Romay, L.; Vieito, M.; Abalo, A.; Alonso-Nocelo, M.; Candamio, S.; Gallardo, E.; Fernández, B.; Abdulkader, I.; et al. Molecular Characterization of Circulating Tumor Cells in Human Metastatic Colorectal Cancer. PLoS ONE 2012, 7, e40476. [Google Scholar] [CrossRef]
- Garg, M. Epithelial, mesenchymal and hybrid epithelial/mesenchymal phenotypes and their clinical relevance in cancer metastasis. Expert Rev. Mol. Med. 2017, 19, e3. [Google Scholar] [CrossRef]
- Polyak, K.; Weinberg, R.A. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9, 265–273. [Google Scholar] [CrossRef] [PubMed]
- Yang, M.-H.; Imrali, A.; Heeschen, C. Circulating cancer stem cells: The importance to select. Chin. J. Cancer Res. 2015, 27, 437–449. [Google Scholar] [CrossRef] [PubMed]
- Kantara, C.; O’Connell, M.; Luthra, G.; Gajjar, A.; Sarkar, S.; Ullrich, R.; Singh, P. Methods for Detecting Circulating Cancer Stem Cells (CCSCs) as a Novel Approach for Diagnosis of Colon Cancer Relapse/Metastasis. Lab. Investig. 2015, 95, 100–112. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Todaro, M.; Gaggianesi, M.; Catalano, V.; Benfante, A.; Iovino, F.; Biffoni, M.; Apuzzo, T.; Sperduti, I.; Volpe, S.; Cocorullo, G.; et al. CD44v6 Is a Marker of Constitutive and Reprogrammed Cancer Stem Cells Driving Colon Cancer Metastasis. Cell Stem Cell 2014, 14, 342–356. [Google Scholar] [CrossRef] [Green Version]
- Zhou, Y.; Xia, L.; Wang, H.; Oyang, L.; Su, M.; Liu, Q.; Lin, J.; Tan, S.; Tian, Y.; Liao, Q.; et al. Cancer stem cells in progression of colorectal cancer. Oncotarget 2018, 9, 33403–33415. [Google Scholar] [CrossRef] [Green Version]
- Ma, L.; Dong, L.; Chang, P. CD44v6 engages in colorectal cancer progression. Cell Death Dis. 2019, 10, 30. [Google Scholar] [CrossRef]
- Nicolazzo, C.; Loreni, F.; Caponnetto, S.; Magri, V.; Vestri, A.R.; Zamarchi, R.; Gradilone, A.; Facchinetti, A.; Rossi, E.; Cortesi, E.; et al. Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer. Oncotarget 2020, 11, 4115–4122. [Google Scholar] [CrossRef]
- Habli, Z.; AlChamaa, W.; Saab, R.; Kadara, H.; Khraiche, M.L. Circulating Tumor Cell Detection Technologies and Clinical Utility: Challenges and Opportunities. Cancers 2020, 12, 1930. [Google Scholar] [CrossRef]
- Gabriel, M.T.; Calleja, L.R.; Chalopin, A.; Ory, B.; Heymann, D. Circulating Tumor Cells: A Review of Non–EpCAM-Based Approaches for Cell Enrichment and Isolation. Clin. Chem. 2016, 62, 571–581. [Google Scholar] [CrossRef] [Green Version]
- Cayrefourcq, L.; Alix-Panabières, C. CTCs as Liquid Biopsy: Where Are We Now? IntechOpen: London, UK, 2019. [Google Scholar] [CrossRef] [Green Version]
- Esmaeilsabzali, H.; Beischlag, T.V.; Cox, M.E.; Parameswaran, A.M.; Park, E.J. Detection and isolation of circulating tumor cells: Principles and methods. Biotechnol. Adv. 2013, 31, 1063–1084. [Google Scholar] [CrossRef]
- Kang, Y.-T.; Kim, Y.J.; Lee, T.; Cho, Y.-H.; Chang, H.J.; Lee, H.-M. Cytopathological Study of the Circulating Tumor Cells filtered from the Cancer Patients’ Blood using Hydrogel-based Cell Block Formation. Sci. Rep. 2018, 8, 15218. [Google Scholar] [CrossRef]
- Fehm, T.; Solomayer, E.; Meng, S.; Tucker, T.; Lane, N.; Wang, J.; Gebauer, G. Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 2005, 7, 171–185. [Google Scholar] [CrossRef]
- Yadegarazari, R.; Hassanzadeh, T.; Majlesi, A.; Keshvari, A.; Monsef Esfahani, A.; Tootoonchi, A.; Shabab, N.; Saidijam, M. Improved Real-Time RT-PCR Assays of Two Colorectal Cancer Peripheral Blood mRNA Biomarkers: A Pilot Study. Iran. Biomed. J. 2013, 17, 15–21. [Google Scholar] [CrossRef]
- Akpe, V.; Kim, T.H.; Brown, C.L.; Cock, I.E. Circulating tumour cells: A broad perspective. J. R. Soc. Interface 2020, 17, 20200065. [Google Scholar] [CrossRef]
- Pallante, P.; Pisapia, P.; Bellevicine, C.; Malapelle, U.; Troncone, G. Circulating Tumour Cells in Predictive Molecular Pathology: Focus on Drug-Sensitive Assays and 3D Culture. ACY 2019, 63, 171–181. [Google Scholar] [CrossRef]
- Cheng, Y.-H.; Chen, Y.-C.; Lin, E.; Brien, R.; Jung, S.; Chen, Y.-T.; Lee, W.; Hao, Z.; Sahoo, S.; Min Kang, H.; et al. Hydro-Seq enables contamination-free high-throughput single-cell RNA-sequencing for circulating tumor cells. Nat. Commun. 2019, 10, 2163. [Google Scholar] [CrossRef]
- Tsai, W.-S.; Chen, J.-S.; Shao, H.-J.; Wu, J.-C.; Lai, J.-M.; Lu, S.-H.; Hung, T.-F.; Chiu, Y.-C.; You, J.-F.; Hsieh, P.-S.; et al. Circulating Tumor Cell Count Correlates with Colorectal Neoplasm Progression and Is a Prognostic Marker for Distant Metastasis in Non-Metastatic Patients. Sci. Rep. 2016, 6, 24517. [Google Scholar] [CrossRef]
- Vafaei, S.; Fattahi, F.; Ebrahimi, M.; Janani, L.; Shariftabrizi, A.; Madjd, Z. Common molecular markers between circulating tumor cells and blood exosomes in colorectal cancer: A systematic and analytical review. CMAR 2019, 11, 8669–8698. [Google Scholar] [CrossRef] [Green Version]
- Horwich, A.; Ross, G. Circulating Tumor Markers. In Principles of Molecular Oncology; Bronchud, M.H., Foote, M.A., Peters, W.P., Robinson, M.O., Eds.; Humana Press: Totowa, NJ, USA, 2000; pp. 111–124. [Google Scholar] [CrossRef]
- Kuppusamy, P.; Govindan, N.; Yusoff, M.M.; Ichwan, S.J.A. Proteins are potent biomarkers to detect colon cancer progression. Saudi J. Biol. Sci. 2017, 24, 1212–1221. [Google Scholar] [CrossRef] [Green Version]
- Ahn, S.B.; Sharma, S.; Mohamedali, A.; Mahboob, S.; Redmond, W.J.; Pascovici, D.; Wu, J.X.; Zaw, T.; Adhikari, S.; Vaibhav, V.; et al. Potential early clinical stage colorectal cancer diagnosis using a proteomics blood test panel. Clin. Proteom. 2019, 16, 34. [Google Scholar] [CrossRef]
- Borrebaeck, C.A.K. Precision diagnostics: Moving towards protein biomarker signatures of clinical utility in cancer. Nat. Rev. Cancer 2017, 17, 199–204. [Google Scholar] [CrossRef]
- Loktionov, A. Biomarkers for detecting colorectal cancer non-invasively: DNA, RNA or proteins? World J. Gastrointest. Oncol. 2020, 12, 124–148. [Google Scholar] [CrossRef]
- Berger, B.M.; Ahlquist, D.A. Stool DNA screening for colorectal neoplasia: Biological and technical basis for high detection rates. Pathology 2012, 44, 80–88. [Google Scholar] [CrossRef]
- Liu, R.; Su, X.; Long, Y.; Zhou, D.; Zhang, X.; Ye, Z.; Ma, J.; Tang, T.; Wang, F.; He, C. A systematic review and quantitative assessment of methylation biomarkers in fecal DNA and colorectal cancer and its precursor, colorectal adenoma. Mutat. Res. 2019, 779, 45–57. [Google Scholar] [CrossRef]
- Worm Ørntoft, M.-B. Review of Blood-Based Colorectal Cancer Screening: How Far Are Circulating Cell-Free DNA Methylation Markers from Clinical Implementation? Clin. Colorectal Cancer 2018, 17, e415–e433. [Google Scholar] [CrossRef]
- Rasmussen, S.L.; Krarup, H.B.; Sunesen, K.G.; Johansen, M.B.; Stender, M.T.; Pedersen, I.S.; Madsen, P.H.; Thorlacius-Ussing, O. Hypermethylated DNA, a circulating biomarker for colorectal cancer detection. PLoS ONE 2017, 12, e0180809. [Google Scholar] [CrossRef] [Green Version]
- Ab Mutalib, N.-S.; Md Yusof, N.F.; Abdul, S.-N.; Jamal, R. Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update. Front. Pharmacol. 2017, 8, 736. [Google Scholar] [CrossRef] [Green Version]
- Ab Mutalib, N.-S.; Baharuddin, R.; Jamal, R. Epigenome-Wide Analysis of DNA Methylation in Colorectal Cancer. In Computational Epigenetics and Diseases; Elsevier: Amsterdam, The Netherlands, 2019; pp. 289–310. [Google Scholar] [CrossRef]
- Luo, X.; Burwinkel, B.; Tao, S.; Brenner, H. MicroRNA Signatures: Novel Biomarker for Colorectal Cancer? Cancer Epidemiol. Biomark. Prev. 2011, 20, 1272–1286. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Abedini, P.; Fattahi, A.; Agah, S.; Talebi, A.; Beygi, A.H.; Amini, S.M.; Mirzaei, A.; Akbari, A. Expression analysis of circulating plasma long noncoding RNAs in colorectal cancer: The relevance of lncRNAs ATB and CCAT1 as potential clinical hallmarks. J. Cell. Physiol. 2019, 234, 22028–22033. [Google Scholar] [CrossRef] [PubMed]
- Chen, B.; Xia, Z.; Deng, Y.-N.; Yang, Y.; Zhang, P.; Zhu, H.; Xu, N.; Liang, S. Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis. Open Biol. 2019, 9, 180212. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bastaminejad, S.; Taherikalani, M.; Ghanbari, R.; Akbari, A.; Shabab, N.; Saidijam, M. Investigation of MicroRNA-21 Expression Levels in Serum and Stool as a Potential Non-Invasive Biomarker for Diagnosis of Colorectal Cancer. Iran. Biomed. J. 2017, 21, 106–113. [Google Scholar] [CrossRef] [PubMed]
- Merker, J.D.; Oxnard, G.R.; Compton, C.; Diehn, M.; Hurley, P.; Lazar, A.J.; Lindeman, N.; Lockwood, C.M.; Rai, A.J.; Schilsky, R.L.; et al. Circulating Tumor DNA Analysis in Patients with Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J. Clin. Oncol. 2018, 36, 1631–1641. [Google Scholar] [CrossRef] [PubMed]
- Stewart, C.M.; Kothari, P.D.; Mouliere, F.; Mair, R.; Somnay, S.; Benayed, R.; Zehir, A.; Weigelt, B.; Dawson, S.-J.; Arcila, M.E.; et al. The value of cell-free DNA for molecular pathology. J. Pathol. 2018, 244, 616–627. [Google Scholar] [CrossRef] [PubMed]
- Fiala, C.; Diamandis, E.P. New approaches for detecting cancer with circulating cell-free DNA. BMC Med. 2019, 17, 159. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Alix-Panabières, C.; Pantel, K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov. 2016, 6, 479–491. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, H.E.; Vuppalapaty, M.; Wilkerson, C.; Renier, C.; Chiu, M.; Lemaire, C.; Che, J.; Matsumoto, M.; Carroll, J.; Crouse, S.; et al. Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients. Front. Oncol. 2020, 10, 572895. [Google Scholar] [CrossRef]
- Ilie, M.; Hofman, V.; Long, E.; Bordone, O.; Selva, E.; Washetine, K.; Marquette, C.H.; Hofman, P. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann. Transl. Med. 2014, 2, 107. [Google Scholar] [CrossRef]
- Agashe, R.; Kurzrock, R. Circulating Tumor Cells: From the Laboratory to the Cancer Clinic. Cancers 2020, 12, 2361. [Google Scholar] [CrossRef]
- Yang, C.; Xia, B.-R.; Jin, W.-L.; Lou, G. Circulating tumor cells in precision oncology: Clinical applications in liquid biopsy and 3D organoid model. Cancer Cell Int. 2019, 19, 341. [Google Scholar] [CrossRef] [Green Version]
- Ciurte, A.; Selicean, C.; Soritau, O.; Buiga, R. Automatic detection of circulating tumor cells in darkfield microscopic images of unstained blood using boosting techniques. PLoS ONE 2018, 13, e0208385. [Google Scholar] [CrossRef]
- Salvianti, F.; Gelmini, S.; Costanza, F.; Mancini, I.; Sonnati, G.; Simi, L.; Pazzagli, M.; Pinzani, P. The pre-analytical phase of the liquid biopsy. N. Biotechnol. 2020, 55, 19–29. [Google Scholar] [CrossRef]
- Dickinson, B.T.; Kisiel, J.; Ahlquist, D.A.; Grady, W.M. Molecular markers for colorectal cancer screening. Gut 2015, 64, 1485–1494. [Google Scholar] [CrossRef] [Green Version]
- Ijzerman, M.J.; de Boer, J.; Azad, A.; Degeling, K.; Geoghegan, J.; Hewitt, C.; Hollande, F.; Lee, B.; To, Y.H.; Tothill, R.W.; et al. Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late. Diagnostics 2021, 11, 103. [Google Scholar] [CrossRef]
Feature | Surface Marker | CTC Identification Marker | CTC Enrichment Technique | Principle/Technology | Pros and Cons | Positive Detection Rate | Study | Clinical Utility | Ref. |
---|---|---|---|---|---|---|---|---|---|
Single specific CSM | EpCAM | CK8, CK18, CK19, HER2, CD45, DAPI, Hoechst | CellSearch® system (Veridex) | Positive enrichment; ferromagnetic beads labeled with EpCAM-antibodies to capture CTCs; identification of CTCs via staining with CK8, CK18, CK19, and HER2; CD45 marker to exclude hematogenous cells; DAPI/Hoechst as marker to identify intact CTCs; CTC enumeration via CellTrack Analysis II | FDA-approved for advanced CRC; loss of EpCAM-negative CTCs; lack of EMT detection; no further downstream analysis | 88.9% (32/36 patients) | Prospective, multicenter, nonrandomized trial (NCT00994864) | Prognosis and prediction of CRC | [74] |
EpCAM | CK20, CD45, DAPI | CellMax platform (CellMax Life) | Positive enrichment; microfluidics chip technology platform; EpCAM-coated SLB to capture CTCs; identification of CTCs via staining with CK20; CTCs enumeration via AI-based automated CellReviewer | Loss of EpCAM-negative CTCs; lack of EMT detection; CTCs intact for downstream analysis | 43.8% (14/32 patients) | Cohort study | CRC screening | [82] | |
EpCAM | CK20, CD45, DAPI | CellMax platform (CellMax Life) | Positive enrichment; CTCs enrichment using EpCAM antibody and stained using CK20 for confirmation; CTC enumeration via an algorithm in CellFinder software | Loss of EpCAM-negative CTCs; lack of EMT detection | 94.5% (307/325 patients) | Bioanalytical assay development and validation study | CRC screening | [30] | |
EpCAM | CK8, CK18, CD45, DAPI | Polymeric CTC chip | Positive enrichment; polymeric microfluidic chip coated with EpCAM for CTC detection; staining with CK8 and CK18 for CTC validation; manual CTC enumeration under an inverted fluorescence microscope | Loss of EpCAM-negative CTCs; easily blocked chips; lack of EMT detection | 92.3% (12/13 patients) | Comparative, longitudinal study | CRC screening; CRC progression monitoring and treatment effects | [83] | |
EpCAM | CK-7, CK-8, CK-18, CK-19, CD45, DAPI, Hoechst | IsoFlux (Fluxion Biosciences) | Positive enrichment; EpCAM- based magnetic separation by flow cytometry to capture CTCs; identification of CTC via CK-7, CK-8, CK-18, and CK-19 markers; CTC enumeration via IsoFlux | Loss of EpCAM-negative CTCs; detection of CTC and MSI status in the peri-operative colorectal surgery setting; lack of EMT detection; no further downstream analysis | 95% (19/20 patients) | Cross-sectional study | CRC screening; CRC progression monitoring and treatment effects | [84] | |
EpCAM or KRAS | CK20, CD45, DAPI | MACS/ microemulsion method | Positive enrichment; EpCAM or KRAS-coated lipid bilayer encapsulated superparamagnetic Fe3O4 nanoparticles balls to capture CTCs with EpCAM expression or KRAS mutation; identification of CTC via CK20 and CD45; KRAS detection via PCR | Detection of CTCs with KRAS mutation; intact CTCs for PCR to validate KRAS mutation | 100% (KRAS) (55/55 patients); 54.5% (EpCAM) (30/55 patients) | Comparative study | KRAS mutation detection; provide diagnosis and treatment of KRAS CRC | [111] | |
EpCAM | pan-CK, CD45, DAPI, Hoechst EpCAM, pan-CK, CD45, DAPI, Hoechst | CellSearch® system (Veridex) GILUPI CellCollector | Positive enrichment; ferromagnetic beads labeled with EpCAM antibodies; identification of CTCs via staining with pan-CK Positive enrichment; novel in vivo CTC detection device with EpCAM, followed by pan-CK/EpCAM (double-staining) for verification | FDA-approved; loss of EpCAM-negative CTCs; lack of EMT detection Loss of EpCAM-negative CTCs; lack of EMT detection | 31.3% (25/80 patients) 41.3% (33/80 patients) | Prospective, single center, investigator-blinded side-by-side comparative study | Prediction of CRC (overall survival based on staging) CRC screening | [96] | |
EpCAM | CK8, CK18, CK19, CD44v6, CD45 | CellSearch® CXC kit (Menarini Silicon Biosystems) | Positive enrichment; ferromagnetic beads labeled with EpCAM-antibodies to capture CTCs; identification of CCSCs via CD44v6 expression | Identification of CTCs with functional attributes of CCSCs via CD44v6 expression | 62.5% (25/40 patients) | Bioanalytical assay development study | mCRC screening; prediction of first-line treatment failure and tumor response in mCRC patients | [124] | |
CD45 | DAPI | Cyttel method | Negative enrichment; CD45-based immunomagnetic system to remove hematogenous cells; CTC identification via imFISH of chromosomes 8 and 17 H1 fluorescent probes, together with DAPI staining | Loss of significant cells; low purity | 58.7% (71/121 patients) | Retrospective study | CRC screening; prediction of survival outcome | [99] | |
Multi-CSM | CD2, CD16, CD19, CD36, CD38, CD45, CD66b, and glycophorin A | CK19, VEGF | RosetteSep™ System (StemCell Technologies) | Positive enrichment; immunodensity procedure; RosetteSep™ tetrameric antibody complexes crosslink unwanted hematogenous cells; isolation of CTCs via density gradient centrifugation, followed by EPISPOT assay where specific secreted proteins were captured by antibody-coated membrane; counting of immunospots (one immunospot corresponded to the protein fingerprint of one viable cell) | Many CTCs harvested; detection of viable CTCs at the single-cell resolution; utilization of CTC-secreted proteins for enrichment; possible for protein characterization | - | Bioanalytical assay development study | CRC screening; possible protein characterization | [100] |
Post multi-CSM | CD45 | pan-CK, EPCAM, VIM, DAPI | RosetteSep™ System (StemCell Technologies) | Pre-negative CD45 enrichment to exclude hematogenous cells; secondary enrichment with EpCAM and CK. Pan-CK, EPCAM, and VIM; CTC enumeration via FCM | Simple, fast, sensitive, and higher recovery to detect potential CTCs (with EMT); CTCs intact for downstream analysis | 46.7% (7/15 patients) | Case control | CRC screening | [112] |
CD45 | EpCAM, CK | EasySep™ (StemCell Technologies) | Pre-negative magnetic CD45 enrichment to exclude hematogenous cells; secondary enrichment with EpCAM and CK; manual CTC enumeration | Little clinical relevance of CTC number to CRC staging; CTC morphology and phenotype closely related to CRC stages | 72% (41/57 patients) | Case control | CRC screening | [102] | |
CD45 | CK18, CEP8, DAPI | SE-iFISH (Cytelligen) | Pre-negative CD45 enrichment to exclude hematogenous cells; secondary enrichment with EpCAM and CK with anti-CK18 and anti-CEP8 | Identification of CTC optimal detection time (after at least 7 postoperative days) | 85% (17/20 patients) | Cross-sectional cohort study | CRC screening and postoperative monitoring | [101] | |
Combined approach | CD45 | CK3 CK3, CK19, MUC1, CD44, CD133, ALDH1, | CellSearch® system (Veridex) CellSearch + cytomorphology + FACS + RT-qPCR | Negative enrichment; CTCs were isolated via CD45+ cells depletion kit and further enriched with anti-CK3-labeled magnetic beads. Combination of several CTC-negative enrichment techniques | CTCs as novel therapeutic targets for nonmetastatic CRC Improved sensitivity and specificity | 54% (34/63 patients) 68.3% (34/43 patients) | Comparative study | CRC screening | [98] |
CTC Enrichment Technique | Advantages | Disadvantages |
---|---|---|
Biophysical isolation (size/microfiltration; density gradient centrifugation) | Quick and simple way to isolate CTCs; Label-free CTC isolation; Rapid processing of large volumes; Applicable to all types of cancers; Inexpensive; Harvest a wider subsets of CTCs | Poor sensitivity due to the loss of some CTCs during migration or formation of CTC aggregates or membrane clogging; Low specificity; Stringent sampling procedure (blood samples collected must be processed immediately and required pre-enrichment step); High contamination risks with hematopoietic cells; Limited due to the heterogeneity in the size and density of CTCs |
Single CSM-based system (a) Positive enrichment | Clinically validated (FDA-approved system); Robust and reproducible; Specific to certain CTC subpopulation depending on the selected marker (epithelial or mesenchymal trait); Advancement in microfluidics technology allows intact cells for downstream analysis | Significant loss of certain CTC subpopulations if a single CSM is used for positive enrichment; Inability to address several parameters (e.g., EMT and mutations) due to the use of single CSM; Inability to address totality of CTCs; Lack of cancer-specific CSMs |
(b) Negative enrichment | Capable of harvesting all types of CTCs if negative enrichment was applied; High CTC viability; No bias based on CSMs; More competent for the discovery of cellular and transcriptomic cancer biomarkers of cancer and downstream analyses such as genetic assays, CTC culture, and xenografts | Low purity and specificity due to the loss of CTCs, especially during negative enrichment; Uncertainty in the accuracy to identify a patient’s CTC status |
Multi-CSM-based system | Higher yield than single CSM-based enrichment systems; High CTC capture efficiency (CTCs of different origins were captured by covering epithelial, mesenchymal, and stem cell markers); Increased analytic sensitivity and specificity than single CSM-based system; Capable of addressing the totality of CTCs; Advancement in microfluidics technology allows intact cells for downstream analysis | Lack of specific combinatorial list of CSMs; Unstandardized protocols when multiple markers are used (e.g., marker concentrations and incubation time); Lack of automated procedures; Limited studies using multiple CSMs for pre-CTC enrichment step |
CCSC-targeted CTC enrichment | Identification of CTCs with cancer stem cell characteristics; More selection of CSMs (including Lrg5, DCLK1, and ANXA2); More specific for mCRC screening; Drug resistance identification | Low population in CTCs; Limited studies |
Nucleic acid-based or functional-based enrichment system/post-CTC analysis and characterization (e.g., immunocytochemistry, qRT-PCR, ddPCR, EPISPOT, NGS, and functional assays) | Detection of viable CTCs; Evaluation of CTC migration and invasion abilities; Ability to address cellular heterogeneity; Capable of CTC characterization; Capable of single cell resolution analysis; Permit CTC morphology analysis; Detection of specific markers not limited to the surface of CTCs | Unstandardized sampling method resulting in significant loss of CTCs and high contamination risks with white blood cells; Unspecific markers for enrichment resulting in the loss of certain CTC subpopulations; Isolated CTCs might not reflect the actual CTC status of patients; Bias or false negative results due to loss of CTCs during the enrichment step; No possibility to recover CTCs |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tieng, F.Y.F.; Abu, N.; Nasir, S.N.; Lee, L.-H.; Ab Mutalib, N.-S. Liquid Biopsy-Based Colorectal Cancer Screening via Surface Markers of Circulating Tumor Cells. Diagnostics 2021, 11, 2136. https://0-doi-org.brum.beds.ac.uk/10.3390/diagnostics11112136
Tieng FYF, Abu N, Nasir SN, Lee L-H, Ab Mutalib N-S. Liquid Biopsy-Based Colorectal Cancer Screening via Surface Markers of Circulating Tumor Cells. Diagnostics. 2021; 11(11):2136. https://0-doi-org.brum.beds.ac.uk/10.3390/diagnostics11112136
Chicago/Turabian StyleTieng, Francis Yew Fu, Nadiah Abu, Siti Nurmi Nasir, Learn-Han Lee, and Nurul-Syakima Ab Mutalib. 2021. "Liquid Biopsy-Based Colorectal Cancer Screening via Surface Markers of Circulating Tumor Cells" Diagnostics 11, no. 11: 2136. https://0-doi-org.brum.beds.ac.uk/10.3390/diagnostics11112136